Kalydeco (ivacaftor)

pCPA File Number: 21106

Negotiation Status:

Concluded with an LOI

Indication(s):

Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation

Sponsor/Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2019-03-29

Negotiation Process Concluded:

2019-07-17